SCHEMBL2462409

SCHEMBL2462409

CCOC(=O)c1cc(-n2cnnn2)cc2c1OC(C)(C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.41
LMNA P02545 2/20 0.40
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ESR2 Q92731 1/20 0.39
RXFP1 Q9HBX9 2/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TSHR P16473 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2469703 0.85 L3MBTL1 (0.40) KDM4EALDH1A1HPGDLMNAL3MBTL1
SCHEMBL2462173 0.77 NOTUM (0.39) ALDH1A1MAPTLMNAL3MBTL1KMT2A
SCHEMBL2431237 0.75 ALDH1A1 (0.47) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL12056188 0.75 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL9983477 0.72 KDM4E (0.40) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2432752 0.72 NPC1 (0.45) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL9983751 0.70 ALDH1A1 (0.39) KDM4EALDH1A1HPGDMAPTLMNA
SCHEMBL2434076 0.70 LMNA (0.52) KDM4EALDH1A1HSD17B10MAPTLMNA
SCHEMBL2468665 0.69 ALDH1A1 (0.41) KDM4EALDH1A1HPGDMAPTPOLB
SCHEMBL9983558 0.67 ALDH1A1 (0.36) KDM4EALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582674-B1 GPR120 RECEPTOR AGONISTS AND USES THEREOF CYMABAY THERAPEUTICS INC (US) 2014-10-01 EP disclosed
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2014-05-01 US disclosed
US-8598374-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-12-03 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-8476308-B2 GPR120 receptor agonists and uses thereof METABOLEX, INC. (US) 2013-07-02 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-23 US disclosed
US-20130109734-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2013-05-02 US disclosed
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2011-12-22 US disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO disclosed
WO-2011159297-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2011-12-22 WO disclosed
EP-2367793-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-09-28 EP disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
US-20100093785-A1 DIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110313003-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM4E 4479/4885ALDH1A1 3347/4885HPGD 2073/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM4E 4479/4885ALDH1A1 3347/4885HPGD 2073/4885
US-20100093785-A1 DIAMINE DERIVATIVES C9, C1S, C1R KDM4E 3773/4885ALDH1A1 3529/4885HPGD 1863/4885
US-20140121246-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM4E 4479/4885ALDH1A1 3347/4885HPGD 2073/4885
US-20130109734-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM4E 4479/4885ALDH1A1 3347/4885HPGD 2073/4885
US-20130131351-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR KDM4E 4479/4885ALDH1A1 3347/4885HPGD 2073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.